Literature DB >> 9342358

Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.

G A Otterson1, W d Chen, A B Coxon, S N Khleif, F J Kaye.   

Abstract

To study the molecular basis for the clinical phenotype of incomplete penetrance of familial retinoblastoma, we have examined the functional properties of three RB mutations identified in the germ line of five different families with low penetrance. RB mutants isolated from common adult cancers and from classic familial retinoblastoma (designated as classic RB mutations) are unstable and generally do not localize to the nucleus, do not undergo cyclin-dependent kinase (cdk)-mediated hyperphosphorylation, show absent protein "pocket" binding activity, and do not suppress colony growth of RB(-) cells. In contrast, two low-penetrant alleles (661W and "deletion of codon 480") retained the ability to localize to the nucleus, showed normal cdk-mediated hyperphosphorylation in vivo, exhibited a binding pattern to simian virus 40 large T antigen using a quantitative yeast two-hybrid assay that was intermediate between classic mutants (null) and wild-type RB, and had absent E2F1 binding in vitro. A third, low-penetrant allele, "deletion of RB exon 4," showed minimal hyperphosphorylation in vivo but demonstrated detectable E2F1 binding in vitro. In addition, each low-penetrant RB mutant retained the ability to suppress colony growth of RB(-) tumor cells. These findings suggest two categories of mutant, low-penetrant RB alleles. Class 1 alleles correspond to promoter mutations, which are believed to result in reduced or deregulated levels of wild-type RB protein, whereas class 2 alleles result in mutant proteins that retain partial activity. Characterization of the different subtypes of class 2 low-penetrant genes may help to define more precisely functional domains within the RB product required for tumor suppression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342358      PMCID: PMC23695          DOI: 10.1073/pnas.94.22.12036

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Identification of a growth suppression domain within the retinoblastoma gene product.

Authors:  X Q Qin; T Chittenden; D M Livingston; W G Kaelin
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

2.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

3.  Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product.

Authors:  W G Kaelin; D C Pallas; J A DeCaprio; F J Kaye; D M Livingston
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

4.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.

Authors:  P L Chen; P Scully; J Y Shew; J Y Wang; W H Lee
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

5.  A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.

Authors:  F J Kaye; R A Kratzke; J L Gerster; J M Horowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma.

Authors:  V Greger; E Passarge; W Höpping; E Messmer; B Horsthemke
Journal:  Hum Genet       Date:  1989-09       Impact factor: 4.132

7.  Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene.

Authors:  T Sakai; N Ohtani; T L McGee; P D Robbins; T P Dryja
Journal:  Nature       Date:  1991-09-05       Impact factor: 49.962

8.  The amino terminus of the retinoblastoma (Rb) protein associates with a cyclin-dependent kinase-like kinase via Rb amino acids required for growth suppression.

Authors:  J M Sterner; Y Tao; S B Kennett; H G Kim; J M Horowitz
Journal:  Cell Growth Differ       Date:  1996-01

9.  Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.

Authors:  B T Lin; S Gruenwald; A O Morla; W H Lee; J Y Wang
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

10.  The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.

Authors:  J A Lees; K J Buchkovich; D R Marshak; C W Anderson; E Harlow
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  30 in total

1.  A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus.

Authors:  S Bolk; A Pelet; R M Hofstra; M Angrist; R Salomon; D Croaker; C H Buys; S Lyonnet; A Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  A parent-of-origin effect in two families with retinoblastoma is associated with a distinct splice mutation in the RB1 gene.

Authors:  Martina Klutz; Dieter Brockmann; Dietmar R Lohmann
Journal:  Am J Hum Genet       Date:  2002-05-09       Impact factor: 11.025

3.  Association Between Genotype and Phenotype in Consecutive Unrelated Individuals With Retinoblastoma.

Authors:  Flore Salviat; Marion Gauthier-Villars; Matthieu Carton; Nathalie Cassoux; Livia Lumbroso-Le Rouic; Catherine Dehainault; Christine Levy; Lisa Golmard; Isabelle Aerts; François Doz; Fidéline Bonnet-Serrano; Stéphanie Hayek; Alexia Savignoni; Dominique Stoppa-Lyonnet; Claude Houdayer
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

4.  Interchangeable Roles for E2F Transcriptional Repression by the Retinoblastoma Protein and p27KIP1-Cyclin-Dependent Kinase Regulation in Cell Cycle Control and Tumor Suppression.

Authors:  Michael J Thwaites; Matthew J Cecchini; Daniel T Passos; Ian Welch; Frederick A Dick
Journal:  Mol Cell Biol       Date:  2017-01-04       Impact factor: 4.272

5.  Genetic screening in patients with Retinoblastoma in Israel.

Authors:  Michal Sagi; Avishag Frenkel; Avital Eilat; Naomi Weinberg; Shahar Frenkel; Jacob Pe'er; Dvorah Abeliovich; Israela Lerer
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

6.  The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.

Authors:  Hai Xiao; David W Goodrich
Journal:  Oncogene       Date:  2005-12-08       Impact factor: 9.867

7.  The N Terminus of the Retinoblastoma Protein Inhibits DNA Replication via a Bipartite Mechanism Disrupted in Partially Penetrant Retinoblastomas.

Authors:  Sergiy I Borysov; Brook S Nepon-Sixt; Mark G Alexandrow
Journal:  Mol Cell Biol       Date:  2015-12-28       Impact factor: 4.272

8.  Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.

Authors:  Yoonsoo Park; Akihito Kubo; Takefumi Komiya; Amy Coxon; Kristin Beebe; Len Neckers; Paul S Meltzer; Frederic J Kaye
Journal:  Cell Cycle       Date:  2008-05-30       Impact factor: 4.534

9.  Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma.

Authors:  Suzanne Richter; Kirk Vandezande; Ning Chen; Katherine Zhang; Joanne Sutherland; Julie Anderson; Liping Han; Rachel Panton; Patricia Branco; Brenda Gallie
Journal:  Am J Hum Genet       Date:  2002-12-18       Impact factor: 11.025

10.  Germline mutations in retinoma patients: relevance to low-penetrance and low-expressivity molecular basis.

Authors:  Hana Abouzeid; Daniel F Schorderet; Aubin Balmer; Francis L Munier
Journal:  Mol Vis       Date:  2009-04-17       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.